title: Collagenase injections for Dupuytren's disease: prospective cohort study assessing 2-year treatment effect durability.
abstract: To assess 2-year durability of joint contracture correction following collagenase injections for Dupuytren's disease.
  
  
  
  Prospective cohort study.
  
  
  
  Orthopaedic Department in Sweden.
  
  
  
  Patients with palpable Dupuytren's cord and active extension deficit (AED) ≥30° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint. A surgeon injected 0.80 mg collagenase into multiple cord parts and performed finger manipulation under local anaesthesia after 24-48 hours. A hand therapist measured joint contracture before and 5 weeks after injection in all treated patients. Of 57 consecutive patients (59 hands), 48 patients (50 hands) were examined by a hand therapist 24-35 months (mean 26) after injection. Five of the patients had received a second injection in the same finger within 6 months of the first injection.
  
  
  
  Primary outcome was proportion of treated joints with ≥20° worsening in AED from 5 weeks to 2 years.
  
  
  
  Between the 5-week and the 2-year measurements, AED had worsened by ≥20° in seven MCP and seven PIP joints (28% of the treated hands; all had received a single injection). Mean AED for the MCP joints was 54° before injection, 6° at 5 weeks and 9° at 2 years and for the PIP joints 30°, 13° and 16°, respectively. For joints with ≥10° contracture at baseline, mean (95 % CI) baseline to 2 years AED improvement was for MCP 49° (41-54) and for PIP 25° (17-32). No treatment-related adverse events were observed at the 2-year follow-up evaluation.
  
  
  
  Two years after collagenase injections for Dupuytren's disease, improvement was maintained in 72% of the treated hands. Complete contracture correction was seen in more than 80% of the MCP but in less than half of the PIP joints.
authors.affiliation: Department of Orthopedics, Hässleholm-Kristianstad-Ystad Hospitals, Hässleholm, Sweden.|Department of Rehabilitation, Hässleholm Hospital, Hässleholm, Sweden.
authors.forename: Anna
authors.initials: A
authors.lastname: Lauritzson
authors.affiliation: Department of Orthopedics, Hässleholm-Kristianstad-Ystad Hospitals, Hässleholm, Sweden.|Department of Clinical Sciences-Orthopedics, Lund University, Lund, Sweden.
authors.forename: Isam
authors.initials: I
authors.lastname: Atroshi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017364:Collagenases / Q000008:administration & dosage / Q000627:therapeutic use*; D004387:Dupuytren Contracture / Q000188:drug therapy*; D005260:Female; D005384:Finger Joint; D006225:Hand / Q000473:pathology*; D006801:Humans; D007267:Injections; D008297:Male; D008662:Metacarpophalangeal Joint; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D017364:Collagenases
keywords: Collagenase; Dupuytren